Biotech firm Belite Bio's Q2 net loss widens on higher R&D expenses

Belite Bio

11/08/2025 11:12

Overview

Belite Bio completed enrollment in Phase 3 PHOENIX trial for geographic atrophy

Co raised $15 mln in registered direct offering, strengthening financial position

Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease by FDA

Outlook

Belite expects DRAGON trial completion by Q4 2025

Company plans to submit DRAGON trial data for drug approval

Belite expects interim analysis for PHOENIX trial

Company advancing Tinlarebant towards key clinical milestones

Result Drivers

BREAKTHROUGH DESIGNATION - Tinlarebant received Breakthrough Therapy Designation for Stargardt disease, highlighting its potential as a first-ever treatment, per CEO Dr. Tom Lin

G&A EXPENSES - Increased spending primarily due to higher share-based compensation expenses

R&D - Higher pass-through expenses related to the PHOENIX trial and manufacturing expenses payments, partially offset by lower DRAGON trial expenses

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$16.32 mln
Q2 Income From Operations
-$17.60 mln
Q2 Operating Expenses
$17.60 mln
Q2 Pretax Profit
-$16.32 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Belite Bio Inc is $92.50, about 24.5% above its August 8 closing price of $69.88

Press Release: ID:nGNX9wNGwH

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)